Clinical trials: Anticoagulation Treatment
Acute Ischemic Stroke, Atrial Fibrillation
Berlin Atrial Fibrillation Registry
Investigator-initiated prospective multicentre hospital-based registry to uncover the proportion of self-reported anticoagulation in stroke patients with atrial fibrillation and assessing the proportion of stroke, intracranial…
- Trial name
- NCT02306824
- Where
- Germany
- Volunteers
- 1,080 people
- Sponsor
- Charite University, Berlin, Germany
Thromboembolism
REVIparin-BRIDging-in a General Practice Setting in GErmany
In view of the fact that little is known about the pre- and post-interventional coagulation management of phenprocoumon patients with reviparin at general practices in Germany, an observational study is being initiated to…
- Trial name
- REVIBRIDGE (NCT02579122)
- Where
- 11 sites in Germany
- Volunteers
- 77 people
- Sponsor
- Mylan Inc.
Bleeding
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
The purpose of this study was to evaluate the hemostatic efficacy of andexanet alfa (andexanet) in participants receiving a factor Xa (FXa) inhibitor (apixaban, rivaroxaban, edoxaban, enoxaparin) who were experiencing an acute…
- Trial name
- NCT02329327
- Testing
- Andexanet
- Where
- 87 sites in United States, Belgium and 7 more
- Volunteers
- 479 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Atrial Fibrillation (AF), Stroke
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
- Trial name
- AZALEA-TIMI 71 (NCT04755283)
- Testing
- Abelacimab, Rivaroxaban
- Where
- 92 sites in United States, Canada and 5 more
- Volunteers
- 1,287 people
- Sponsor
- Anthos Therapeutics, Inc.
Extracorporeal Membrane Oxygenation Complication, Anticoagulants
Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation
This study will evaluate heparin as compared to bivalirudin for systemic anticoagulation in adult patients that require extracorporeal membrane oxygenation (ECMO).
- Trial name
- BIV-ECMO2 (NCT03965208)
- Testing
- Bivalirudin, Unfractionated heparin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Legacy Health System
Chronic Hemodialysis Patients
Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients
Atrial fibrillation is the most frequent cardiac rhythm disorder and its prognosis is essentially marked by the risk of embolic events.
- Trial name
- CARD-AXA (NCT05410275)
- Testing
- Rivaroxaban
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Tours
Pulmonary Thromboembolism
Thromboembolic Events in Severe COVID-19 Patients
The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19.
- Trial name
- COVICLOT (NCT04405869)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
COPD Exacerbation, PTE - Pulmonary Thromboembolism
The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism
Anticoagulation is the most important treatment for pulmonary thromboembolism (PTE). The thromboembolism risk is especially high in patients with chronic obstructive pulmonary disease (COPD) exacerbations.
- Trial name
- NCT03185845
- Testing
- Warfarin
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
COVID19 Pneumonia
Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent Covid-19 or infection with SARS-CoV-2 or therapeutic agent to…
- Trial name
- CORIMMUNO-COAG (NCT04344756)
- Testing
- Tinzaparin or unfractionated heparin
- Where
- 3 sites in France
- Volunteers
- 808 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Endstage Renal Disease
LMWH Infusion as Anticoagulation for Home HD
There is a lack of data in the literature about the use of low-molecular weight heparin (LMWH) as anticoagulation for nocturnal home hemodialysis (NHHD).
- Trial name
- NCT02957877
- Testing
- Nadroparin, Unfractionated heparin
- Where
- Hong Kong
- Volunteers
- 12 people
- Sponsor
- Alice Ho Miu Ling Nethersole Hospital
Renal Replacement Therapy
A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects
This study is divided into Stage I and Stage II. It is planned to include 156 subjects who need CRRT treatment for more than 48 hours.
- Trial name
- NCT05602129
- Testing
- HSK36273, Heparin sodium
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Atrial Fibrillation, Stroke
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
- Conditions
- Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
- Trial name
- ARC (NCT01747746)
- Testing
- Rivaroxaban, Warfarin and Enoxaparin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Cook County Health
Atrial Fibrillation, Coronary Artery Disease
Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and antiplatelet in patients with stable CAD (coronary artery stenosis ≥50% on medical treatment or revascularized stable CAD [≥ 12 months…
- Conditions
- Atrial Fibrillation, Coronary Artery Disease, Stable Angina, Stable Chronic Angina
- Trial name
- EPIC-CAD (NCT03718559)
- Testing
- Edoxaban Monotherapy, Edoxaban plus Single Antiplatelet Agent
- Where
- 18 sites in South Korea
- Volunteers
- 1,040 people
- Sponsor
- Gi-Byoung Nam
Cardiopathy, Chagas Disease
Outcomes of an Anticoagulation Clinic in an University Hospital
A clinical trial designed to compare the oral anticoagulation control obtained by an anticoagulation clinic and the usual medical care in Chagas and Non-Chagas disease patients.
- Conditions
- Cardiopathy, Chagas Disease, Hemorrhage, Thrombosis
- Trial name
- NCT01006486
- Testing
- Anticoagulation clinic, Standard anticoagulation care
- Where
- Brazil
- Volunteers
- 280 people
- Sponsor
- Federal University of Minas Gerais
Thromboembolism
Evaluation of ReX-C System in Measurement and Improvement of Patients' Adherence.
The study aims to evaluate the safety, usability and efficacy of the ReX-C - a novel medication management system - in measurement and improvement of adherence, in patients receiving oral anti-coagulation therapy for the…
- Trial name
- NCT03424330
- Testing
- ReX-C intervention, Standard of Care
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Dosentrx Ltd.
Ischemic Stroke, Oral Anticoagulation
Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or…
- Conditions
- Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment
- Trial name
- ASPERA (NCT06823466)
- Where
- 47 sites in Croatia, Denmark and 13 more
- Volunteers
- 200 people
- Sponsor
- University of L'Aquila
Myocardial Infarction
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients…
- Trial name
- NCT00433966
- Testing
- Bivalirudin, Unfractionated heparin, Bare metal stent
- Where
- United States
- Volunteers
- 3,602 people
- Sponsor
- Cardiovascular Research Foundation, New York
Venous Thromboembolic Disease, Kidney Failure, Chronic
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
Patients with end stage renal disease (ESRD) are at significantly increased risk of thrombosis and bleeding relative to those with normal renal function which makes anticoagulation particularly challenging.
- Trial name
- NCT04818151
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 14,914 people
- Sponsor
- Johns Hopkins University
Atrial Fibrillation, Coronary Artery Disease
Antithrombotic Strategy for AF Patients With High Risk CAD
Anticoagulation therapy is recommended for patients with atrial fibrillation (AF) in order to prevent ischemic stroke and systemic embolism.
- Trial name
- ADAPT AFFIRM (NCT06866665)
- Testing
- Anticoagulation Monotherapy, Combination therapy
- Volunteers
- 1,400 people
- Sponsor
- Yonsei University
Pulmonary Hypertension
Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
Sickle cell disease (SCD) is often referred to as a hypercoagulable state. However, the contribution of coagulation activation to the pathogenesis of SCD remains uncertain.
- Trial name
- NCT01036802
- Testing
- Warfarin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of North Carolina, Chapel Hill